Wire
Stevanato Group Says Alina-Based Liraglutide Products Receive European Authorizations
Stevanato Group (STVN) said Thursday liraglutide-based combination products using its Alina pen injector platform have received marketing authorizations in multiple European countries.The authorizations cover liraglutide therapies for diabetes and weight management and include the Alina 30 and Alina 50 configurations, the company said.The approvals relate to finished combination products held by their respective marketing authorization holders, Stevanato Group said.Shares of the company were 1.8% lower in Thursday trading.Price: $20.03, Change: $-0.39, Percent Change: -1.89%
$STVN
